Advagraf — Tacrolimus 1 mg, 50 pcs, Astellas

Advagraf 1 mg — Tacrolimus Prolonged-Release 1 mg, 50 Capsules

Product code: 487

5200₴ 5650₴ -8% On order · from 14 days
1
Active ingredient
Dosage form Capsules
Capsules per pack 50
Packaging Blisters in a box

Advagraf is an original prolonged-release immunosuppressive medicinal product designed to prevent transplant rejection in patients following solid organ transplantation. The active pharmaceutical ingredient is tacrolimus at a strength of 1 mg supplied as prolonged-release hard capsules (Tacrolimus prolonged-release hard capsules 1 mg). The product is developed and manufactured by the global pharmaceutical corporation Astellas Pharma.

Advagraf is an advanced prolonged-release formulation of tacrolimus (derived from the Prograf technology). Unlike conventional immediate-release tacrolimus (administered twice daily), Advagraf is engineered for administration once daily (in the morning). The innovative matrix capsule structure ensures gradual and uniform release of the active ingredient throughout the gastrointestinal tract over 24 hours, flattening peak blood plasma concentrations while sustaining steady therapeutic immunosuppressive exposure.

Supplied in an outer carton containing 50 capsules (5 blister strips of 10 capsules each). Intended exclusively for prescription use under the strict therapeutic drug monitoring (TDM) supervision of a transplant specialist.

Key Clinical Features and Advantages of Advagraf 1 mg:

  • ✅ Once-Daily Dosing: Significantly improves patient adherence and compliance compared to twice-daily regimens.
  • ✅ Pharmacokinetic Peak Smoothing: Lower diurnal concentration fluctuation amplitude reduces concentration-dependent adverse reaction risks.
  • ✅ Reliable Graft Protection: High efficacy in preventing acute and chronic rejection in kidney and liver allograft recipients.
  • ✅ Original Astellas Quality: Stringent Japanese manufacturing standards ensuring active substance purity and process reproducibility.
  • ✅ Convenient 1 mg Strength: Enables precise individualized dose titration guided by routine laboratory blood testing.

Advagraf 1 mg is supplied as prolonged-release hard capsules.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Tacrolimus (as tacrolimus monohydrate) — 1 mg.
  • Excipients: Hypromellose, ethylcellulose, hypromellose (matrix agent), magnesium stearate, lactose monohydrate. Capsule shell: titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172), gelatin, sodium lauryl sulfate. Imprinting ink (shellac, lecithin, simethicone, colorants).

Packaging and Presentation: Prolonged-release hard gelatin capsules with a light yellow body and light red cap (for the 1 mg strength) containing white to off-white powder or granules. 10 capsules per blister strip. 5 blister strips (total 50 capsules) are packaged in an outer carton displaying Advagraf 1 mg along with Astellas Pharma corporate graphics and prescribing information.

Pharmacodynamics:
Tacrolimus is a potent macrolide immunosuppressive agent. At the molecular level, tacrolimus action is mediated by binding to a cytosolic protein (FKBP12) responsible for intracellular drug accumulation. The tacrolimus-FKBP12 complex selectively inhibits calcineurin, a calcium- and calmodulin-dependent enzyme, preventing calcium-dependent induction of cytokine gene transcription (such as interleukin-2 and interferon-gamma). Consequently, the drug potently suppresses T-lymphocyte activation, cytotoxic T-cell proliferation, and primary cell-mediated immune responses against allografts.

Pharmacokinetics:

  • Absorption: Following oral administration of Advagraf, tacrolimus gastrointestinal absorption is extended due to matrix prolonged-release kinetics. Peak plasma concentration (Tmax) is achieved approximately 2 hours post-dose. Absolute bioavailability is low and variable (approximately 20% to 25%).
  • Distribution: Tacrolimus partitions extensively into erythrocytes (blood-to-plasma concentration ratio approximately 20:1). In plasma, approximately 99% of drug is bound to proteins (albumin and alpha-1-acid glycoprotein).
  • Metabolism: Extensively metabolized in the liver and intestinal wall via cytochrome P450 enzyme systems, predominantly cytochrome P450 3A4 (CYP3A4), yielding multiple metabolites (mostly inactive).
  • Elimination: Excreted predominantly via the biliary route into feces (less than 1% excreted unchanged renally). Terminal elimination half-life (T1/2) averages 30 to 40 hours.

Advagraf is indicated in adult patients for:

  • Kidney Transplant Rejection Prophylaxis: Primary immunosuppression in adult kidney allograft recipients (in combination with other immunosuppressive agents).
  • Liver Transplant Rejection Prophylaxis: Primary immunosuppression in adult liver allograft recipients.
  • Resistant Rejection Treatment: Treatment of graft rejection episodes resistant to other immunosuppressive regimens.

Advagraf is administered orally strictly once daily in the morning, on an empty stomach or at least 2 to 3 hours after a meal (food intake significantly reduces drug absorption). Capsules must be swallowed whole with water; they must not be broken, chewed, or crushed.

Dosing Regimen:
Dosage is individualized by the attending transplant specialist based on target blood trough concentrations and clinical tolerability:

  • Primary Therapy (Kidney): Recommended starting daily dose is 0.10–0.30 mg/kg body weight once daily.
  • Primary Therapy (Liver): Recommended starting daily dose is 0.05–0.15 mg/kg body weight once daily.
  • Conversion from Prograf (twice daily) to Advagraf (once daily): Conversion is performed on a 1:1 (mg:mg) total daily dose basis administered in the morning.

Administration of Advagraf is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to tacrolimus, other macrolides, or any excipient (including lactose).
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding (except in cases of absolute necessity where potential benefit outweighs maternal-fetal risk).
  • Concurrent Medications: Co-administration with agents causing severe pharmacokinetic interactions (potent CYP3A4 inhibitors/inducers without therapeutic monitoring).

Tacrolimus is metabolized by hepatic CYP3A4. Any agents affecting this enzyme may alter blood tacrolimus concentrations:

  • CYP3A4 Inhibitors (Increase Tacrolimus Levels & Toxicity Risk): Antifungals (ketoconazole, itraconazole, fluconazole), macrolide antibiotics (erythromycin, clarithromycin), calcium channel blockers (diltiazem, verapamil), HIV protease inhibitors, grapefruit juice. Dose reduction and frequent monitoring required.
  • CYP3A4 Inducers (Decrease Tacrolimus Levels & Rejection Risk): Anticonvulsants (phenytoin, carbamazepine, phenobarbital), antibiotics (rifampicin, rifabutin), St. John's Wort (Hypericum perforatum). Dose escalation required.
  • Nephrotoxic Agents: Concurrent use with aminoglycosides, amphotericin B, ganciclovir, or NSAIDs increases nephrotoxicity risk.

Pregnancy:
Tacrolimus crosses the placenta. Use during pregnancy should be considered only if the expected benefit outweighs potential fetal risks. Pregnant patients receiving tacrolimus require rigorous clinical monitoring.

Lactation:
Tacrolimus is excreted into human breast milk. Because serious adverse reactions in nursing infants cannot be ruled out, breastfeeding must be discontinued during treatment.

The adverse event profile of tacrolimus is extensive; many reactions are concentration-dependent:

  • Renal System (Nephrotoxicity): Renal impairment, elevated blood urea nitrogen and serum creatinine (very common). Routine monitoring required.
  • Endocrine & Metabolism: Hyperglycemia, diabetes mellitus, hyperkalemia, hypomagnesemia, hypocalcemia, hypercholesterolemia.
  • Nervous System: Headache, tremor (very common), insomnia, paresthesias, seizures, confusion.
  • Cardiovascular System: Hypertension, tachycardia, peripheral edema.
  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, constipation, dyspepsia.
  • Infections: Heightened susceptibility to viral, bacterial, and fungal infections due to immunosuppression.

Symptoms:
Clinical experience with overdose is limited. Accidental overdoses have resulted in tremor, headache, nausea, vomiting, infections, urticaria, lethargy, transient blood urea nitrogen and serum creatinine elevations, and hyperkalemia.

Treatment:
No specific antidote exists. Supportive and symptomatic care should be initiated. Due to high molecular weight and extensive erythrocyte/protein binding, tacrolimus is not dialyzable.

Storage Requirements for Advagraf 1 mg:

  • 🌡️ Temperature Range: Store in original packaging protected from moisture and light at temperatures below 25 °C.
  • 💧 Blister Integrity: Capsules should be removed from the blister immediately prior to administration.
  • 👶 Safety Precautions: Keep out of reach of children.
  • ⏳ Shelf Life: Stated on outer carton and blister foil. Do not use past expiration date. Prescription-only medicine.

To verify authenticity of genuine Advagraf 1 mg manufactured by Astellas Pharma, inspect the following features:

  • ✅ Corporate Logo: Distinctive Astellas corporate logo printed on the outer carton and blister foil.
  • ✅ Packaging Markings: Laser-printed Batch No., manufacturing date, and expiration date matching carton and blisters, displaying Advagraf 1 mg.
  • ✅ Capsule Appearance: Prolonged-release capsules feature a dual-tone design (light yellow body and light red cap) with distinct dosage imprinting.
  • ✅ Prescribing Information: Includes an official multi-language or localized product leaflet inside the carton.
On order · from 14 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 07.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00